U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. For Consumers
  3. Health Fraud Scams
  4. Fraudulent Coronavirus Disease 2019 (COVID-19) Products
  1. Health Fraud Scams

Fraudulent Coronavirus Disease 2019 (COVID-19) Products

The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from firms selling unapproved products and making false or misleading claims, including, by pursuing warning letters, seizures, injunctions or criminal prosecutions against products and firms or individuals that violate the law.

Report a website that you think is illegally selling human drugs, animal drugs, medical devices, biological products, foods, dietary supplements or cosmetics.

Warning Letters

Additional COVID-19 related warning letters can be found on the Agency's Warning Letters webpage.
 

An asterisk (*) under the table column "Corrective Status” indicates the firm’s listed product(s) are no longer sold for the prevention, treatment, mitigation, diagnosis or cure of coronavirus disease 2019 (COVID-19). This status only concerns sale of the listed product(s) for the prevention, treatment, mitigation, diagnosis or cure of coronavirus disease 2019 (COVID-19) and in no way indicates whether the listed products otherwise comply with the laws and regulations enforced by FDA. FDA will monitor all listed firms for recurrence of the conduct cited in the warning letters.
 
Product name linked to Flickr image when available.
Although the recipient of this letter appears to have addressed the specific violations cited in the Warning Letter, the agency continues to have concerns pertaining to the firm’s marketing of regenerative medicine products.
Back to Top